Open Access<p>Clinical Investigation of the Efficacy and Safety of Anlotinib with Immunotherapy in Advanced Non-Small Cell Lung Cancer as Third-Line Therapy: A Retrospective Study</p>
Author(s) -
Shengjie Yang,
Wenjie Zhang,
Qing Chen,
Qisen Guo
Publication year - 2020
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s280096
Subject(s) - medicine , common terminology criteria for adverse events , lung cancer , oncology , adverse effect , immunotherapy , progressive disease , response evaluation criteria in solid tumors , hazard ratio , proportional hazards model , multivariate analysis , progression free survival , cancer , confidence interval , disease , chemotherapy
This study was designed to assess the clinical efficacy and safety of anlotinib with immunotherapy in advanced non-small cell lung cancer as third-line therapy.